SCHEMBL9433142

SCHEMBL9433142

CC(C)CCC(=O)c1cccnc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLOD2 O00469 2/20 0.56
HDAC1 Q13547 2/20 0.54
HDAC8 Q9BY41 1/20 0.54
CTNNB1 P35222 1/20 0.52
WNT3A P56704 1/20 0.52
ALDH1A1 P00352 3/20 0.50
APP P05067 1/20 0.50
GAA P10253 1/20 0.50
HCAR3 P49019 1/20 0.50
HCAR2 Q8TDS4 1/20 0.50
PLOD3 O60568 1/20 0.50
PLOD1 Q02809 1/20 0.50
TRPA1 O75762 1/20 0.49
F7 P08709 1/20 0.49
F3 P13726 1/20 0.49
SARM1 Q6SZW1 1/20 0.49
SIRT2 Q8IXJ6 1/20 0.49
SIRT6 Q8N6T7 1/20 0.49
SIRT1 Q96EB6 1/20 0.49
SIRT3 Q9NTG7 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30173794 1.00 PLOD2 (0.56) PLOD2HDAC1HDAC8CTNNB1WNT3A
SCHEMBL7543318 0.88 HDAC1 (0.50) PLOD2HDAC1HDAC8CTNNB1WNT3A
SCHEMBL23792310 0.86 PLOD2 (0.51) PLOD2HDAC1HDAC8CTNNB1WNT3A
SCHEMBL28522671 0.84 PLOD2 (0.50) PLOD2HDAC1HDAC8CTNNB1WNT3A
SCHEMBL7075878 0.84 PLOD2 (0.69) PLOD2HDAC1HDAC8CTNNB1WNT3A
SCHEMBL23992253 0.83 HDAC1 (0.54) PLOD2HDAC1HDAC8CTNNB1WNT3A
SCHEMBL14073817 0.83 PLOD2 (0.59) PLOD2HDAC1HDAC8ALDH1A1APP
SCHEMBL15445292 0.83 KMT2A (0.59) PLOD2HDAC1HDAC8CTNNB1WNT3A
SCHEMBL29020091 0.81 PLOD2 (0.50) PLOD2HDAC1HDAC8CTNNB1WNT3A
SCHEMBL552724 0.81 PLOD2 (0.61) PLOD2HDAC1HDAC8CTNNB1WNT3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12157731-B2 EIF4E inhibitors and uses thereof PIC Therapeutics, Inc. (US) 2024-12-03 US disclosed
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-12-14 US disclosed
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-12-14 US disclosed
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-12-14 US disclosed
US-11753403-B2 EIF4E inhibitors and uses thereof PIC Therapeutics, Inc. (US) 2023-09-12 US disclosed
US-11753403-B2 EIF4E inhibitors and uses thereof PIC Therapeutics, Inc. (US) 2023-09-12 US disclosed
US-11753403-B2 EIF4E inhibitors and uses thereof PIC Therapeutics, Inc. (US) 2023-09-12 US disclosed
EP-4114529-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. (US) 2023-01-11 EP disclosed
US-20220356178-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2022-11-10 US disclosed
WO-2021178488-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. (US) 2021-09-10 WO disclosed
WO-2021178488-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. (US) 2021-09-10 WO disclosed
US-5352793-A Sunscreen compounds ICI AUSTRALIA OPERATIONS PROPRIETARY LIMITED (AU) 1994-10-04 US disclosed
EP-0287603-B1 SUNSCREEN COMPOSITIONS AND COMPOUNDS FOR USE THEREIN ICI AUSTRALIA OPERATIONS (AU) 1993-12-22 EP disclosed
EP-0287603-A4 SUNSCREEN COMPOSITIONS AND COMPOUNDS FOR USE THEREIN 1991-12-27 EP disclosed
US-5000946-A Sunscreen compositions and compounds for use therein ICI AUSTRALIA OPERATIONS PROPRIETARY LIMITED, 1 NICHOLSON STREET, MELBOURNE, VICTORIA 3001, AUSTRALIA, A COMPANY OF AUSTRALIA 1991-03-19 US disclosed
EP-0356843-A2 Process for the preparation of heteroaromatic aldehydes and ketones BASF Aktiengesellschaft (DE) 1990-03-07 EP disclosed
EP-0287603-A1 SUNSCREEN COMPOSITIONS AND COMPOUNDS FOR USE THEREIN. ICI AUSTRALIA OPERATIONS (AU) 1988-10-26 EP disclosed
WO-1988002251-A1 SUNSCREEN COMPOSITIONS AND COMPOUNDS FOR USE THEREIN ICI AUSTRALIA OPERATIONS PROPRIETARY LIMITED (AU) 1988-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 PLOD2 4577/4885HDAC1 1462/4885HDAC8 1494/4885
US-12157731-B2 EIF4E inhibitors and uses thereof EIF4E, EIF4EBP1, EIF4A1 PLOD2 4577/4885HDAC1 1462/4885HDAC8 1494/4885
US-11753403-B2 EIF4E inhibitors and uses thereof EIF4E, EIF4EBP1, EIF4A1 PLOD2 4577/4885HDAC1 1462/4885HDAC8 1494/4885
US-20220356178-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 PLOD2 4577/4885HDAC1 1462/4885HDAC8 1494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.